Skip to main content
SpringerLink
Log in

Nintedanib in advanced NSCLC of adenocarcinoma histology: a profile of its use

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Nintedanib (Vargatef®) is a triple angiokinase inhibitor that potently blocks the proangiogenic pathways mediated by vascular endothelial growth factor receptors, platelet-derived growth factor receptors and fibroblast growth factor receptors. In the phase 3 LUME-Lung 1 study in patients with advanced non-small cell lung cancer (NSCLC), the subgroup of patients with adenocarcinoma histology who have progressed after first line chemotherapy experienced a significant improvement in progression-free and overall survival with oral nintedanib + docetaxel relative to placebo + docetaxel, with greater benefits seen in patients with rapidly progressing disease. Nintedanib is the first antiangiogenic agent to have shown a survival benefit in the second-line treatment of these patients. Nintedanib combination therapy has a generally manageable tolerability profile.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5):v1–27.

    Article  PubMed  CAS  Google Scholar 

  2. National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): non-small cell lung cancer (version 2.2018). Fort Washington: National Comprehensive Cancer Network®, Inc.; 2017.

  3. Weiss JM, Stinchcombe TE. Second-line therapy for advanced NSCLC. Oncologist. 2013;18(8):947–53.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii27–39.

    Article  PubMed  Google Scholar 

  5. Crino L, Metro G. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev. 2014;23(131):79–91.

    Article  PubMed  Google Scholar 

  6. Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891–925.

    Article  PubMed  CAS  Google Scholar 

  7. Vargatef (nintedanib): summary of product characteristics. London: European Medicines Agency; 2017.

  8. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–82.

    Article  PubMed  CAS  Google Scholar 

  9. Roth GJ, Heckel A, Colbatzky F, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem. 2009;52(14):4466–80.

    Article  PubMed  CAS  Google Scholar 

  10. Kutluk Cenik B, Ostapoff KT, Gerber DE, et al. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol Cancer Ther. 2013;12(6):992–1001.

    Article  PubMed  CAS  Google Scholar 

  11. Hilberg F, Brandstetter I. Efficacy of BIBF 1120, a potent triple angiokinase inhibitor, in models of human non-small cell lung cancer is augmmented by chemotherapy [abstract no. C7-03]. J Thorac Oncol. 2007;2(8):S380.

    Article  Google Scholar 

  12. Xiang QF, Wang F, Su XD, et al. Effect of BIBF 1120 on reversal of ABCB1-mediated multidrug resistance. Cell Oncol (Dordr). 2011;34(1):33–44.

    Article  PubMed  CAS  Google Scholar 

  13. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2):143–55.

    Article  PubMed  CAS  Google Scholar 

  14. Hanna NH, Kaiser R, Sullivan RN, et al. Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): a randomized, double-blind, phase III trial. Lung Cancer. 2016;102:65–73.

    Article  PubMed  Google Scholar 

  15. Gaschler-Markefski B, Sikken P, Heymach JV, et al. Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open. 2017;2(1):e000102.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Lee-Cervantes D, Cruz-Rico G, Michel-Tello D, et al. Soluble angiogenic factors as predictive biomarkers of response to docetaxel plus nintedanib as second line therapy in NSCLC [abstract no. P2.03b-083]. J Thorac Oncol. 2017;12(1 Suppl):S986.

    Article  Google Scholar 

  17. Arrieta O, Garcia-Perez F, Michel-Tello D, et al. PET-CT with 68Ga-RGD as biomarker of response to nintedanib plus docetaxel as second line therapy in NSCLC [abstract no. P2.03b-088]. J Thorac Oncol. 2017;12(1 Suppl):S989–90.

    Article  Google Scholar 

  18. Stopfer P, Rathgen K, Bischoff D, et al. Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers. Xenobiotica. 2011;41(4):297–311.

    Article  PubMed  CAS  Google Scholar 

  19. Novello S, Kaiser R, Mellemgaard A, et al. Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. Eur J Cancer. 2014;51(3):317–26.

    Article  PubMed  CAS  Google Scholar 

  20. Gottfried M, Bennouna J, Bondarenko I, et al. Efficacy and safety of nintedanib plus docetaxel in patients with advanced lung adenocarcinoma: complementary and exploratory analyses of the phase III LUME-Lung 1 study. Target Oncol. 2017;12(4):475–85.

    Article  PubMed  Google Scholar 

  21. Wu YL, Cheng Y, Kim BS, et al. Efficacy of nintedanib/docetaxel in East Asian patients with lung adenocarcinoma (ADE): analysis from the LUME-Lung 1 study [abstract no. 438P]. Ann Oncol. 2015;26(Suppl 9):ix133.

    Article  Google Scholar 

  22. Data on file. Ingelheim am Rhein: Boehringer Ingelheim International GmbH; 2017.

  23. Reck M, Mellemgaard A, von Pawel J, et al. Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxel. Lung Cancer. 2015;90(2):267–73.

    Article  PubMed  Google Scholar 

  24. Reck M, Mellemgaard A. Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib. Biologics. 2015;9:47–56.

    PubMed  PubMed Central  CAS  Google Scholar 

  25. Hilberg F, Haslinger C, Garin Chesa P, et al. Molecular correlates of clinical benefit from antiangiogenic therapy for patients with lung adenocarcinoma: a hypothesis [abstract no. e22080]. J Clin Oncol. 2014;32(15 Suppl).

  26. Reck M, Heigener D, Reinmuth N. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Rev Clin Pharmacol. 2014;7(5):579–90.

    Article  PubMed  CAS  Google Scholar 

  27. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther. 2011;4:43–58.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Popat S, Mellemgaard A, Fahrbach K, et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2015;11(3):409–20.

    Article  PubMed  CAS  Google Scholar 

  29. Popat S, Mellemgaard A, Reck M, et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options. Future Oncol. 2017;13(13):1159–71.

    Article  PubMed  CAS  Google Scholar 

  30. Dhillon S. Nintedanib: a review of its use as second-line treatment in adults with advanced non-small cell lung cancer of adenocarcinoma histology. Target Oncol. 2015;10(2):303–10.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The manuscript was updated from Targeted Oncology 2015;10(2):303–10 [30], and was reviewed by: I. Bondarenko, Dnipropetrovsk Medical Academy, City Multi-Field Clinical Hospital #4, Dnipropetrovsk, Ukraine; A. Mellemgaard, Consultant, Bornholms Hospital, Copenhagen, Denmark; A. Wozniak, Department of Oncology, Karmanos Cancer Institute, Detroit, MI, USA. During the peer review process, Boehringer Ingelheim Pharmaceuticals, Inc. provided a scientific accuracy review of their data at the request of the journal editor. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflict of interest

S. Dhillon is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest. Additional information about this Adis Drug Review can be found at http://www.medengine.com/Redeem/DDFCF0605237D6D6.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Nintedanib in advanced NSCLC of adenocarcinoma histology: a profile of its use. Drugs Ther Perspect 34, 157–164 (2018). https://doi.org/10.1007/s40267-018-0481-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-018-0481-7

Search

Navigation